223 related articles for article (PubMed ID: 8988742)
1. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.
Katsuki Y; Shibutani Y; Aoki D; Nozawa S
Cancer; 1997 Jan; 79(1):169-76. PubMed ID: 8988742
[TBL] [Abstract][Full Text] [Related]
2. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
3. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
4. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
Sasagawa S; Shimizu Y; Kami H; Takeuchi T; Mita S; Imada K; Kato S; Mizuguchi K
Steroids; 2008 Feb; 73(2):222-31. PubMed ID: 18061638
[TBL] [Abstract][Full Text] [Related]
5. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid.
Katsuki Y; Sasagawa S; Takano Y; Shibutani Y; Aoki D; Udagawa Y; Nozawa S
Drugs Exp Clin Res; 1997; 23(2):45-62. PubMed ID: 9309380
[TBL] [Abstract][Full Text] [Related]
6. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
Banno K; Kisu I; Yanokura M; Tsuji K; Masuda K; Ueki A; Kobayashi Y; Yamagami W; Nomura H; Susumu N; Aoki D
Int J Oncol; 2012 Jun; 40(6):1755-62. PubMed ID: 22366992
[TBL] [Abstract][Full Text] [Related]
7. Development of a mouse model for testing therapeutic agents: the anticancer effect of dienogest on endometrial neoplasms.
Saito F; Tashiro H; Yamaguchi M; Honda R; Ohba T; Suzuki A; Katabuchi H
Gynecol Endocrinol; 2016; 32(5):403-7. PubMed ID: 26680656
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
9. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
10. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
Okada H
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
[TBL] [Abstract][Full Text] [Related]
11. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
12. Morphological and biochemical features of a medroxyprogesterone acetate (MPA)-resistant MCF-7 breast cancer cell line.
Gibelli N; Zibera C; Sica G; Carbone M; Pedrazzoli P; Robustelli della Cuna G
Anticancer Res; 1994; 14(1A):37-43. PubMed ID: 7909420
[TBL] [Abstract][Full Text] [Related]
13. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
14. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells.
Schneck H; Ruan X; Seeger H; Cahill MA; Fehm T; Mueck AO; Neubauer H
Gynecol Endocrinol; 2013 Feb; 29(2):160-3. PubMed ID: 23116217
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
17. [Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells].
Ishida H; Okabe M; Gomi K; Horiuchi R
Gan To Kagaku Ryoho; 1993 Apr; 20(5):625-30. PubMed ID: 8470920
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines.
Navo MA; Smith JA; Gaikwad A; Burke T; Brown J; Ramondetta LM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):483-9. PubMed ID: 18004570
[TBL] [Abstract][Full Text] [Related]
19. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation.
Abe M; Yamashita J; Ogawa M
Cancer; 2000 May; 88(9):2000-9. PubMed ID: 10813710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
